A NURSE who sought out treatment for “embarrassing” incontinence issues claims she’s been left with regular urinary tract ...
MedPage Today on MSN10h
Newer Biologics Tied to Fewer Infections for Older Patients With Psoriatic DiseaseBiologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults ...
Using a high-pressure water jet to operate on an enlarged prostate can better preserve the ability to ejaculate, compared with standard laser surgery ...
"I went to Williamsburg Bathhouse last Sunday and got a terrible UTI within 48 hours," one commenter said, adding that they ...
The FDA approved oral iptacopan (Fabhalta; Novartis) to reduce proteinuria in adults with C3 glomerulopathy (C3G), according ...
Heart disease patients now have another treatment option. The U.S. Food and Drug Administration has approved Alnylam ...
Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...
Venxxiva ™ (tiopronin delayed-release tablet) has been made available for the treatment of cystinuria.
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
Zacks Investment Research on MSN9h
FDA Approves Novartis Drug for Rare Kidney Disease TreatmentNovartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved ...
Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback